Lixte Biotechnology (LIXT)

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

A(z) Lixte Biotechnology Holdings, Inc. Common Stock (LIXT) részvény mai árfolyama , ami NaN% elmozdulást tükröz a piac nyitása óta. A vállalat piaci kapitalizációja jelenleg 24,98 M $, a napi kereskedési volumen pedig  részvény. A korábbi záró ár volt.

Készen állsz? Kövesd az alábbi lépéseket, vagy olvasd el útmutatónkat a(z) hogyan vásárolj Lixte Biotechnology részvényt a Krakenen, kezdve 10 dollárral.